Search

Your search keyword '"Martin R. Farlow"' showing total 542 results

Search Constraints

Start Over You searched for: Author "Martin R. Farlow" Remove constraint Author: "Martin R. Farlow"
542 results on '"Martin R. Farlow"'

Search Results

1. CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET

2. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

3. Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer’s disease

4. A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer’s disease

5. Herpes simplex virus and rates of cognitive decline or whole brain atrophy in the Dominantly Inherited Alzheimer Network

6. Interleukin-1β drives NEDD8 nuclear-to-cytoplasmic translocation, fostering parkin activation via NEDD8 binding to the P-ubiquitin activating site

7. White matter alterations in early‐stage Alzheimer's disease: A tract‐specific study

8. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

9. Tau-related white-matter alterations along spatially selective pathways

10. Temporal stability of the ventral attention network and general cognition along the Alzheimer’s disease spectrum

11. Head injury is associated with tau deposition on PET in MCI and AD patients

12. Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease

13. Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET

14. Prediction and Classification of Alzheimer’s Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers

15. The Influence of Cerebrospinal Fluid Abnormalities and APOE 4 on PHF-Tau Protein: Evidence From Voxel Analysis and Graph Theory

16. New Perspective for Non-invasive Brain Stimulation Site Selection in Mild Cognitive Impairment: Based on Meta- and Functional Connectivity Analyses

17. Performing Sparse Regularization and Dimension Reduction Simultaneously in Multimodal Data Fusion

18. Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients

19. Resting state network modularity along the prodromal late onset Alzheimer's disease continuum

20. Corrigendum: Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images

21. Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images

22. Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia

23. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease

24. 2307

25. Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease.

26. Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning.

27. Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer’s Disease

28. Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer’s disease

29. New insights into the genetic etiology of Alzheimer's disease and related dementias

31. Amyloid and Tau Pathology are Associated with Cerebral Blood Flow in a Mixed Sample of Nondemented Older Adults with and without Vascular Risk Factors for Alzheimer’s Disease

32. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

33. Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy

34. Modeling autosomal dominant Alzheimer's disease with machine learning

35. Measuring Subjective Cognitive Decline in Older Adults: Harmonization Between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments

36. Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)

37. AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains

38. White matter alterations in early‐stage Alzheimer's disease: A tract‐specific study

39. A landscape of the genetic and cellular heterogeneity in Alzheimer disease

40. Association of retinal nerve fiber layer thickness with temporal lobe atrophy

41. Hypertension and race affect cerebral blood flow and cognition in older adults without dementia

42. Brain activation during episodic scene encoding is associated with amyloid and tau levels in amyloid‐positive older adults

43. Circular RNA detection identifies circPSEN1 alterations in brain specific to Autosomal Dominant Alzheimer Disease

44. Multi-tissue proteomics identifies molecular signatures for sporadic and genetically defined Alzheimer disease cases

45. Measuring Subjective Cognitive Decline in Older Adults: Harmonization between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments

46. Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trial

47. Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions

48. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

49. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

50. Author response: Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease

Catalog

Books, media, physical & digital resources